Product image of Neupogen (Filgrastim) supplied by GNH India

Neupogen

Active Ingredient:
Filgrastim
Origin:
EU

Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as an injection solution for subcutaneous use. It treats chemotherapy‑induced neutropenia and other neutropenic conditions in patients receiving cancer therapy, bone‑marrow transplantation, or with severe chronic neutropenia.

GNH India supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neupogen (filgrastim) is used to manage neutropenia, a condition of low neutrophil counts, across several clinical settings.

  • Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk in patients receiving cytotoxic chemotherapy.
  • Neutropenia associated with bone marrow transplantation: supports neutrophil recovery after hematopoietic stem cell transplant.
  • Severe chronic neutropenia or agranulocytosis: increases neutrophil production in patients with persistent low counts.

How It Works

  • Filgrastim binds to the specific granulocyte colony‑stimulating factor (G‑CSF) receptor on hematopoietic progenitor cells, activating intracellular signaling pathways that stimulate proliferation, differentiation, and activation of neutrophil precursors, thereby accelerating the restoration of normal neutrophil numbers in the peripheral blood.

Side Effects

Neupogen may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Bone pain: mild to moderate discomfort in bones or joints.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Fever: transient elevation in body temperature.
  • Headache: mild headache.

Serious or Rare Side Effects

  • Splenic rupture: rare but potentially life‑threatening.
  • Acute respiratory distress syndrome (ARDS): severe lung inflammation.
  • Allergic reactions: anaphylaxis, urticaria, or angioedema.

Precautions & Warnings

When prescribing Neupogen, clinicians should consider several safety and handling precautions.

  • Indication verification: ensure neutropenia is confirmed and the patient meets approved criteria.
  • Monitoring blood counts: perform regular complete blood counts to track neutrophil response.
  • Bone pain management: assess and treat bone pain, which may require analgesics.
  • Splenic assessment: monitor for abdominal pain that could indicate splenic enlargement.
  • Concomitant chemotherapy: adjust timing relative to cytotoxic agents to avoid overlapping toxicities.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Neupogen can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Chemotherapy agents with overlapping myelosuppressive effects: may reduce benefit of filgrastim.
  • High‑dose corticosteroids: can blunt neutrophil response.
  • Antimicrobial agents that cause neutropenia: concurrent use may counteract intended effect.

Moderate Interactions (Monitor Closely)

  • Immunosuppressants (e.g., cyclosporine): monitor neutrophil counts.
  • Live attenuated vaccines: assess infection risk due to altered immune response.
  • Lithium: may enhance leukocytosis, requiring blood count monitoring.

Frequently Asked Questions

Neupogen is a filgrastim‑based injectable indicated to reduce the duration of neutropenia and lower infection risk in patients who develop low neutrophil counts after chemotherapy, during bone‑marrow transplantation, or who have severe chronic neutropenia or agranulocytosis.

Filgrastim binds to the G‑CSF receptor on hematopoietic stem and progenitor cells, triggering intracellular signaling that promotes the proliferation, differentiation, and activation of neutrophil precursors, thereby accelerating the recovery of functional neutrophils in the bloodstream.

The dose of Neupogen is individualized by the prescribing clinician based on the patient’s weight, the severity of neutropenia, and the underlying treatment protocol. Exact dosing regimens are determined by the healthcare professional and should not be altered without medical guidance.

Safety data for filgrastim in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Neupogen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

The primary alternative to filgrastim is pegfilgrastim, a long‑acting G‑CSF that requires a single injection per chemotherapy cycle. Filgrastim (Neupogen) is shorter‑acting and may be administered daily, offering flexibility for dose adjustments, whereas pegfilgrastim provides convenience with fewer injections but less dosing flexibility.

Neupogen must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Once prepared for injection, it should be used promptly and any unused portion discarded according to local regulations.

Neupogen is given as a subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to minimize local irritation, and aseptic technique must be followed to prevent contamination.

Serious risks associated with Neupogen include splenic rupture, severe allergic reactions such as anaphylaxis, and acute respiratory distress syndrome (ARDS). Patients should be instructed to seek immediate medical attention if they experience severe abdominal pain, difficulty breathing, or signs of an allergic reaction.

Neupogen is contraindicated in individuals with known hypersensitivity to filgrastim or any of its excipients. Caution is advised for patients with myeloid malignancies, uncontrolled infections, or those receiving concurrent myelosuppressive therapies where the benefit‑risk balance is uncertain.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Filgrastim

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT